Ocuphire Invited to Present Clinical Data on Nyxol® and APX3330 at the American Academy of Ophthalmology 2021 Annual Meeting and Eyecelerator/AAO Meeting
November 01, 2021 09:30 ET
|
Ocuphire Pharma
FDA Approves First Pharmaceutical Therapy to Treat Presbyopia; Nyxol on Track to Start Phase 3 Presbyopia Trials in First Half of 2022 Ocuphire Uniquely Positioned in Developing Late-Stage Innovative...
Ocuphire Announces Publications Featuring the Ref-1 Protein, a Transcription Factor Regulator, as a Novel Therapeutic Target for the Treatment of Neovascular Retinal Diseases
October 07, 2021 07:00 ET
|
Ocuphire Pharma
New Review Publications Underscore the Role of the APE1/Ref-1 Protein in Multiple Pro-angiogenic Pathways Associated with Neovascular Eye Disease Including Diabetic Retinal Diseases and Age-Related...
Ocuphire’s Clinical Phase 2b Oral Drug Candidate APX3330 for Retina to be Featured at the OIS Retina@ASRS and ASRS 2021 Annual Meeting
October 01, 2021 08:49 ET
|
Ocuphire Pharma
FARMINGTON HILLS, Mich., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing...
Ocuphire Pharma Presenting at Three Upcoming Healthcare Conferences This Fall
September 27, 2021 07:00 ET
|
Ocuphire Pharma
Benzinga Healthcare Small Cap Conference on September 29-30, 2021 Ophthalmology Futures Forums: European Virtual Forum on October 7, 2021 Alliance Global Partners Biotech & Specialty...
Ocuphire Pharma, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
September 03, 2021 17:00 ET
|
Ocuphire Pharma
FARMINGTON HILLS, Mich., Sept. 03, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), today announced that the Compensation Committee of its Board of Directors, which is composed...
Ocuphire Pharma Presenting at Four Conferences in September
September 02, 2021 07:00 ET
|
Ocuphire Pharma
Euro Forums 2021 Virtual Retina Forum on September 8, 2021 HC Wainwright Virtual 23rd Annual Global Investment Conference on September 13-15, 2021 Oppenheimer Virtual Fall Healthcare Life...
Ocuphire Announces Financial Results for the Second Quarter 2021 and Provides Corporate Update
August 12, 2021 07:00 ET
|
Ocuphire Pharma
Continued Momentum in Nyxol® Programs with Announcement of Positive Top-Line Results from VEGA-1 Phase 2 Trial in Presbyopia Nyxol plus Low-Dose Pilocarpine Phase 2 Trial Results Show Potential for...
Ocuphire Pharma Presenting at Two Conferences in August
August 06, 2021 07:30 ET
|
Ocuphire Pharma
Canaccord Genuity 41st Annual Growth Conference being held virtually on August 10-12, 2021 HC Wainwright Ophthalmology Virtual Conference on August 17, 2021 FARMINGTON HILLS, Mich., Aug. 06,...
Ocuphire Announces Publication in the Journal of Cellular Signaling Featuring its Oral Ref-1 Inhibitor APX3330 in Phase 2 Trial for the Treatment of Retinal Disease
July 22, 2021 08:00 ET
|
Ocuphire Pharma
Highlights Favorable Safety Profile of the Oral New Chemical Entity APX3330 and Its Novel Anti-Angiogenic and Anti-Inflammatory Mechanism of Action Properties Relevant to a Broad Range of Retinal...
Ocuphire Selected to Present at Multiple Ophthalmic Conferences in July
July 13, 2021 09:00 ET
|
Ocuphire Pharma
Positive Results from Phase 2 Presbyopia (VEGA-1) and Phase 3 Reversal of Mydriasis (MIRA-2) Studies to be Presented at 2021 ASCRS Annual Meeting in Las Vegas Ocuphire Presenting Nyxol® + Low Dose...